Treatment for Parkinson’s disease
The invention relates to the administration of an oligosaccharide molecule able to contrast the typical symptomatology of neurodegenerative diseases. In particular, this treatment is able to counteract the motor symptomatology typical of Parkinson’s disease with a biochemical and functional recovery of dopaminergic neurons, and a potential consequent improvement of patients’ clinical conditions and in terms of quality of life.
Parkinson’s disease is a neurodegenerative illness whose typical motor symptoms result from the death of the substantia nigra cells (dopaminergic neurons). Currently the treatment of these symptoms occurs by pharmacological and surgical means. The researchers have identified a molecule whose administration leads to a reduction of the motor symptoms typical of Parkinson’s disease through a biochemical and functional recovery of dopaminergic neurons (data obtained in vivo). This molecule could also bring positive results in the treatment of other neurodegenerative diseases such as Alzheimer’s and Multiple Sclerosis or in reducing the symptoms related to the aging process. The chemical structure of this molecule (oligosaccharide) has no critical factors on the toxicity profile and it is able to pass the blood-brain barrier remaining unchanged.
- Parkinson’s disease;
- Alzheimer’s disease;
- Neurodegenerative diseases;
- Aging and maintenance of cognitive abilities.
- Therapeutic approach able to reduce symptoms;
- Molecules able to pass unchanged the blood-brain barrier (BBB);
- Effective therapy for the treatment of sporadic Parkinson’s disease.